The specificity, efficacy and safety profiles of biologics make them good candidates for the treatment of autoimmune diseases, and the significant unmet medical needs in both large and orphan indications makes this an attractive field of research for industry companies. Scientists are striving to identify novel targets and mechanisms of action, and to apply exciting new product platforms and technologies in this space.  But major challenges remain in the areas of demonstrating improved efficacy over established standards of care, identifying quality preclinical research models and stratifying responder populations to improve clinical studies and applications. The 3rd Annual Biologics for Autoimmune Diseases presents a focused meeting that explores the application of new science and technology in the development of a next generation of effective and safe therapeutics in autoimmunity and inflammation. 

Topics will include, but are not limited to:

Emerging Targets and Mechanisms of Action
•             Complement system
•             Identification of novel targets for early onset diseases
•             Innate immune mechanisms
•             Novel mechanisms of action
•             Single cell technologies for target discovery
•             T cell targeting agents; T cell reprogramming

Discovery and Development of Biologics for Orphan Autoimmune Indications
•             Clinical development strategies for biologics in orphan indications
•             Efficacy models for biologics in rare autoimmune diseases
•             Expanding indications for approved biologics into rare diseases
•             Regulatory strategies; gaining accelerated approval
•             Where are the new opportunities in autoimmune diseases?

Biomarker Discovery and Development
•             Development of companion diagnostics
•             Genomic analysis for autoimmune diseases
•             Measuring performance of biologic agents versus current standards of care
•             Patient selection biomarkers
•             Understanding the molecular basis for the heterogeneity of autoimmune disease targets

Research Models for Preclinical and Clinical Studies
•             Analytical packages for accelerated approvals
•             Drug safety models
•             Mitigation of safety issues: infusion reaction, infection, induction of autoimmunity
•             Preclinical models of efficacy
•             Trial design considerations

Applications of Emerging Biologics Platforms in Autoimmune Indications
•             Antibody-drug conjugates
•             Bispecifics and multispecifics
•             Cell therapy
•             Immunotherapy combinations
•             Stem cells
•             Vaccines

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract.  Remember to specify the conference that you are interested in and please provide your full contact information.

Deadline for submission is Friday, September 25, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471